Conor Killmurray

The National Comprehensive Cancer Network has announced their recommendation for the use of pacritinib in the first line and second line setting for treating patients with myeloproliferative neoplasms.

Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.

In pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia who had a non-response to blinatumomab and a high-disease burden, worse outcomes were observed , according to retrospective research.

The evolving landscape for treating multiple myeloma has seen significant improvement for patients, giving them better options. One of the key regimens added to this landscape is the use of a new quadruplet regimen.

Chimeric antigen receptor expansion by day 10 could be an early biomarker to predict response and survival in patients with B-cell lymphoma.

Successful CAR T-cell production was achieved in all 11 patients who underwent apheresis and cell production but were still alive at the time of infusion, according to result presented during the BMT- EHA 4th European CAR T-Cell Meeting.

In a subgroup analysis of patients with non-small cell lung cancer who have EGFR sensitizing mutations, the regimen of atezolizumab plus bevacizumab plus carboplatin, and paclitaxel, had a stonger survival benefit compared to other therapies.

The addition of bevacizumab to erlotinib did not demonstrated improvement in overall survival in patients with EGFR-mutant non–small cell lung cancer treated in a phase 3 study.

Prerna Mewawalla, MD, looks back at a decade of advancements in the multiple myeloma space.

The phase 3 EQUATOR clinical trial has been initiated in the United States for the treatment of patients with acute graft-versus-host disease.

Promising early results have been announcement from a phase 2 study of tisotumab vedotin in select patients with squamous cell carcinoma of the head and neck.

The FDA has approved pacritinib for the treatment of patients with myelofibrosis and severe thrombocytopenia.

Today’s electronic medical records allow providers to have accurate, up-to-date, and complete information, provide quicker access than a physical file, improve security and privacy, improve patient communication, enable safer prescriptions, and even cut costs

A subgroup analysis of lenvatinib plus pembrolizumab showed similar results to the global population of patients with advanced renal cell carcinoma who participated in the phase 3 CLEAR trial.

In the largest study of bone marrow-derived macrophages in post hematopoietic stem cell transplantation patients with a hematologic malignancy, results showed that donor derived cells from the myeloablative transplants accounted for 4.1-25% of microglial cells.

Concomitant mutations, and high PD-L1 expression may be associated with an unfavorable clinical response to second-generation tyrosine kinase inhibitors in patients with ALK-rearrange non–small cell lung cancer.

The FDA has granted a fast-track designation to the G-quadruplex stabilizer CX-5461 for BRCA1/2, PALB2, or HRD mutations in their breast or ovarian cancer.

Treatment with a triplet combination of pembrolizumab, binimetinib and bevacizumab was associated with an observed clinical benefit in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer.

Olaparib and pembrolizumab appear to be a safe and tolerable combination therapy for patients with advanced cholangiocarcinoma.

Pending results from the ENGOT-en9/LEAP-001 will determine whether the combination of pembrolizumab and lenvatinib prolongs survival more than chemotherapy in patients with endometrial cancer.

Results from the phase 2 OCEAN trial show that osimertinib is effective in treating central nervous system metastases from non–small cell lung cancer in patients with certain mutations.

Updated findings from the CARTITUDE-1 trial presented at the 2021 ASH Annual Meeting and Exposition show that the use of a CAR T-cell therapy resulted in durable responses that lasted at nearly 2 years of follow-up across most subgroups with relapsed/refractory multiple myeloma.

The use of ibrutinib plus loncastuximab tesirine induced encouraging anti-tumor activity and a manageable safety profile in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma, according to results from an interim analysis of the LOTIS-3 trial.

The incidence of adverse events appeared to increase when bendamustine was added to venetoclax for the treatment of patients with released or refractory chronic lymphocytic leukemia

The FDA has extended the review period of the new drug application for pacritinib as treatment of patients with myelofibrosis and severe thrombocytopenia.

In a post-hoc analysis of the CheckMate 9ER trial, researchers found that, along with additional efficacy benefits, the combination of nivolumab plus cabozantinib had manageable adverse events.

Looking at 2 years' worth of data for patients with ERBB2-negative breast cancer, a study showed that the anti-inflammatory agent celecoxib had no disease free survival benefit.

Progression-free survival remained unaffected in patients with advanced biliary tract cancer after clinicians added either ramucirumab or merestinib to first-line chemotherapy.

The combination of dendritic cell-based immunotherapy in the second-line of treatment for patients with ovarian cancer proves beneficial.